Analysts See $-0.11 EPS for VIVUS, Inc. (VVUS)

October 13, 2018 - By Vivian Park

Investors sentiment decreased to 0.69 in Q2 2018. Its down 0.31, from 1 in 2018Q1. It is negative, as 10 investors sold VIVUS, Inc. shares while 16 reduced holdings. 11 funds opened positions while 7 raised stakes. 18.50 million shares or 15.99% less from 22.03 million shares in 2018Q1 were reported.
Blackrock Inc accumulated 2.05M shares. Elkhorn Prtn Lp stated it has 10,800 shares. Hbk Sorce Advisory Limited Liability Co reported 40,000 shares stake. Deutsche Bankshares Ag reported 1.39 million shares. Barclays Public Limited Com has 0% invested in VIVUS, Inc. (NASDAQ:VVUS) for 131,775 shares. First Limited Partnership owns 112,975 shares. Sg Americas Securities Ltd Liability Corporation invested in 0% or 20,175 shares. Next Financial Group Incorporated accumulated 33,057 shares or 0.01% of the stock. Jane Street Grp Incorporated Ltd Llc reported 0% in VIVUS, Inc. (NASDAQ:VVUS). Northern Corporation reported 279,536 shares or 0% of all its holdings. Maple Capital Mgmt accumulated 24,500 shares or 0% of the stock. 103,137 are owned by State Street Corporation. 11,000 are held by Schulhoff Inc. Citigroup has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Natl Bank Of Montreal Can reported 60,000 shares.

Analysts expect VIVUS, Inc. (NASDAQ:VVUS) to report $-0.11 EPS on November, 6.They anticipate $0.05 EPS change or 83.33 % from last quarter’s $-0.06 EPS. After having $-0.12 EPS previously, VIVUS, Inc.’s analysts see -8.33 % EPS growth. The stock increased 4.18% or $0.19 during the last trading session, reaching $4.74. About 59,621 shares traded. VIVUS, Inc. (NASDAQ:VVUS) has declined 38.95% since October 14, 2017 and is downtrending. It has underperformed by 54.57% the S&P500.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company has market cap of $50.50 million. The firm offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It currently has negative earnings. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension.

More news for VIVUS, Inc. (NASDAQ:VVUS) were recently published by:, which released: “VIVUS to Present at the BIO Investor Forum on October 17, 2018” on October 10, 2018.‘s article titled: “VIVUS Regains Compliance with Nasdaq Listing Requirements” and published on September 26, 2018 is yet another important article.

VIVUS, Inc. (NASDAQ:VVUS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News